|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway (DCC 2-2) |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6382-12
|
||||||||
|
6. House ID# 314000000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly James |
Date | 10/15/2020 4:21:16 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordable Care Act (ACA); ACA Regulations; ACA Stabilization; Health Reform; Risk Adjustment; Opioids; Individual Health Care Costs; Mental Health; Transparency; Surprise Billing; Prior Authorization; All Payer Claims Database (APCD); Medicare for All; Maternal Health; Community Health; 2021 Notice of Benefit and Payment Parameters (NBPP); COVID-19 Response/Relief Packages; Health Care Access/Privacy; Risk Corridors; COBRA; Telehealth; CDC Guidance Testing; COVID-19; Mental Health Parity (MHPAEA); Premium Credits; ACA Tax Credits; Black Maternal Health
HR 266 (116th Congress), Paycheck Protection Program and Health Care Enhancement Act, by Rep. Betty McCollum (D-MN). Responds to the COVID-19 outbreak by providing additional funding for small business loans, health care providers, and COVID-19 testing.
HR 748 (116th Congress), Coronavirus Aid, Relief, and Economic Security (CARES) Act, by Rep. Joe Courtney (D-CT). Responds to the COVID-19 outbreak and its impact on the economy, public health, state and local governments, individuals, and businesses.
HR 2328 (116th Congress), Community Health Investment, Modernization, and Excellence Act of 2019, by Rep. Tom OHalleran (D-AZ). Reauthorize and extend funding for community health centers and the National Health Service Corps.
HR 2781 (116th Congress), EMPOWER for Health Act of 2019, by Rep. Jan Schakowsky (D-IL). Reauthorize certain programs relating to the health professions workforce.
HR 3630 (116th Congress), No Surprises Act, by Rep. Frank Pallone, Jr. (D-NJ). Protect health care consumers from surprise billing practices.
HR 5826 (116th Congress), Consumer Protections Against Surprise Medical Bills Act of 2020, by Rep. Richard Neal (D-MA). Prevent certain cases of out-of-network surprise medical bills, strengthen health care consumer protections, and improve health care information transparency.
HR 6074 (116th Congress), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, by Rep. Nita Lowey (D-NY). Provides $8.3 billion in emergency funding for federal agencies to respond to the coronavirus outbreak.
HR 6201 (116th Congress), First Coronavirus Response Act, by Rep. Nita Lowey (D-NY). Makes emergency supplemental appropriations for the fiscal year ending September 30, 2020.
HR 6545 (116th Congress), Health Insurance Marketplace Affordability Act of 2020, by Rep. Stephanie Murphy (D-FL). Provide an age rating adjustment to the applicable percentage used to determine the credit for coverage under qualified health plans.
HR 6763 (116th Congress), COVID-19 Racial and Ethnic Disparities Task Force Act of 2020, by Rep. Robin Kelly (D-IL). Establish a COVID-19 Racial and Ethnic Disparities Task Force to gather data about disproportionately affected communities and provide recommendations to combat the racial and ethnic disparities in the COVID-19 response.
HR 6800 (116th Congress), HEROES Act, by Rep. Nita Lowey (D-NY). Responds to the COVID-19 outbreak and its impact on the economy, public health, state and local governments, individuals, and businesses.
HR 6810 (116th Congress), Health Care Protection Act, by Rep. Rodney Davis (R-IL). Establish a Health Care Protection Program Fund to provide grants to employers to ensure continuity of coverage under a group health plan through the COVID-19 pandemic, to provide for premium assistance for COBRA benefits.
HR 7723 (116th Congress), Behavioral Health Coordination and Communication Act of 2020, by Rep.Joe Kennedy (D-MA). Establish the position of Interagency Coordinator for Behavioral Health to coordinate the programs and activities of the Federal Government relating to mental health.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Executive Office of the President (EOP), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Advantage; Medicaid Expansion; Medicaid; Privacy; Medicare Prescription Drug Prices; CMS; CHIP, MACRA; Provider Funding; Medicaid FMAP Increase; Coronavirus Medicaid Response; Rate Notice and Call Letter; Star Ratings
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). Establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Opioids; CREATES Act; Drug Pricing
HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration.
HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin.
HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain.
HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |